TargetMol

Zoledronic acid monohydrate

Product Code:
 
TAR-T21299
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T21299-25mg25mg£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21299-50mg50mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21299-100mg100mg£175.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21299-200mg200mg£228.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21299-500mg500mg£306.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Zoledronic acid hydrate is a synthetic imidazole bisphosphonate analog with anti-bone-resorption activity.
CAS:
165800-06-6
Formula:
C5H12N2O8P2
Molecular Weight:
290.105
Pathway:
Apoptosis; ; Autophagy
Purity:
0.98
SMILES:
O.OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O
Target:
Apoptosis; Autophagy

References

1. Albani-Campanario M , G Buend?a-D?az, Flores-Islas M , et al. [Zoledronic acid-based uveitis: a case report and a bibliography review][J]. Ginecolog?a Y Obstetricia De M?xico, 2012, 80(5):355-9. 2. Huang WW, Huang C, Liu J, Zheng HY, Lin L. Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis. PLoS One. 2012;7(7):e4078doi: 10.1371/journal.pone.004078Epub 2012 Jul 26. Review. PubMed PMID: 22844410; PubMed Central PMCID: PMC3406041. 3. Zhang J, Wang R, Zhao YL, Sun XH, Zhao HX, Tan L, Chen DC, Hai-Bin X. Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis. Asian Pac J Trop Med. 2012 Sep;5(9):743-8. doi: 10.1016/S1995-7645(12)60118-7. Review. PubMed PMID: 22805729. 4. Hadji P, Coleman R, Gnant M, Green J. The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann Oncol. 2012 Nov;23(11):2782-90. doi: 10.1093/annonc/mds169. Epub 2012 Jun 2Review. PubMed PMID: 22730099; PubMed Central PMCID: PMC3477882.